title: p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site.
abstract: We initiated a retrospective study to determine whether p53 status and thymidylate synthase (TS) protein expression in primary colon tumors influence recurrence and survival for patients with stage II colon cancer. Tumor specimens from 45 consecutive untreated patients with stage II colon cancer were examined for p53 and TS protein expression using immunohistochemistry. The median follow-up was 5.1 years. Eighteen patients had left-sided tumors, and 27 had right-sided tumors. Fourteen of 45 patients (31%) developed recurrence. p53 overexpression was detected in the tumors of 18 patients (40%); 10 patients (55%) with p53 overexpression recurred; and 4 of 27 (15%) without evidence of p53 overexpression recurred (P = 0.002). High TS expression was detected in the tumors of 16 patients (36%): 8 patients (50%) with high TS expression recurred, and 6 patients (21%) with low TS expression recurred (P = 0.027). Patients with p53 overexpression had a significantly poorer survival than did those patients without p53 overexpression (P < 0.001). High TS expression was associated with poor survival (P = 0.004). p53 overexpression and high TS expression were significantly associated with left-sided tumors (P = 0.003 and P = 0.022). Thirteen of 16 patients (81%) with high TS expression also overexpressed p53, and 24 of 29 patients (81%) with low TS expression did not manifest p53 overexpression (P < 0.001). p53 and TS expression in primary stage II colon cancer are associated and appear to influence recurrence and survival. In this pilot study, left-sided tumors demonstrate significantly more p53 overexpression and significantly higher TS expression than do right-sided tumors, which may explain the significantly poorer survival for patients with left-sided tumors.
authors.affiliation: Division of Medical Oncology, University of Southern California/Norris Comprehensive Cancer Center, University of Southern California School of Medicine, Los Angeles 90033, USA. lenz@hsc.usc.edu
authors.forename: H J
authors.initials: HJ
authors.lastname: Lenz
authors.forename: K D
authors.initials: KD
authors.lastname: Danenberg
authors.forename: C G
authors.initials: CG
authors.lastname: Leichman
authors.forename: B
authors.initials: B
authors.lastname: Florentine
authors.forename: P G
authors.initials: PG
authors.lastname: Johnston
authors.forename: S
authors.initials: S
authors.lastname: Groshen
authors.forename: L
authors.initials: L
authors.lastname: Zhou
authors.forename: Y P
authors.initials: YP
authors.lastname: Xiong
authors.forename: P V
authors.initials: PV
authors.lastname: Danenberg
authors.forename: L P
authors.initials: LP
authors.lastname: Leichman
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003110:Colonic Neoplasms / Q000201:enzymology / Q000378:metabolism* / Q000401:mortality; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009363:Neoplasm Proteins / Q000378:metabolism*; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D012189:Retrospective Studies; D016019:Survival Analysis; D013940:Thymidylate Synthase / Q000378:metabolism*; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*
chemical_list: D009363:Neoplasm Proteins; D016159:Tumor Suppressor Protein p53; D013940:Thymidylate Synthase